<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520295</url>
  </required_header>
  <id_info>
    <org_study_id>BSctDNA-GC</org_study_id>
    <nct_id>NCT04520295</nct_id>
  </id_info>
  <brief_title>ctDNA Screening in Advanced HER2 Positive Gastric Cancer</brief_title>
  <official_title>Predictive Biomarkers Screening by ctDNA Detection in Advanced HER2 Positive Gastric Cancer Patients Treated by Trastuzumab Plus Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify molecular biomarker panel correlating with efficacy of trastuzuamb in advanced&#xD;
      HER2 positive gastric cancer patients. To observe the molecular evolution of HER2 positive&#xD;
      gastric cancer during treatment by ctDNA detection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Molecular events including gene mutation, fusion and amplification will be detected by next&#xD;
      generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from&#xD;
      peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will&#xD;
      be collected at baseline, first surveillance after treatment and disease progression. For&#xD;
      HER2 negative patients, samples will be collected at baseline as negative control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in molecular biomarkers at time on best overall response</measure>
    <time_frame>36 months</time_frame>
    <description>Molecular biomarkers including gene mutation, amplification and fusion were detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from patients during treatment. The list of genes included in OncoScreen Plus panelTM is provided as supplementary file.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in molecular biomarkers at time on disease progression</measure>
    <time_frame>36 months</time_frame>
    <description>Molecular biomarkers including gene mutation, amplification and fusion were detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from patients during treatment. The list of genes included in OncoScreen Plus panelTM is provided as supplementary file.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HER2-positive Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>HER2 positive cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ctDNA screening</intervention_name>
    <description>Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.</description>
    <arm_group_label>HER2 positive cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HER2 positive gastric cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/female patients aged over 18 years.&#xD;
&#xD;
          2. Histologically confirmed gastric adenocarcinoma. Gastric tumors should be treatment&#xD;
             na√Øve unresectable or metastatic disease, or recurrence over 6 months after finish of&#xD;
             adjuvant chemotherapy.&#xD;
&#xD;
          3. HER2 status is confirmed by IHC/FISH. HER2 positive: IHC 3+ or IHC 2+ plus FISH&#xD;
             positive, HER2 negative: IHC 0/1+ or IHC 2+ plus FISH negative.&#xD;
&#xD;
          4. At least one measurable lesion should be confirmed by imaging examination.&#xD;
&#xD;
          5. Eligible peripheral blood samples&#xD;
&#xD;
          6. Patients with enough organ function and performance status (ECOG 0-2) can tolerant&#xD;
             chemotherapy.&#xD;
&#xD;
          7. For HER2 positive patients, trastuzumab should be used as first-line treatment. The&#xD;
             regimen of chemotherapy should be platinum plus oral fluorouracil.&#xD;
&#xD;
          8. For HER2 negative patients, clinicopathological characteristics should be matched to&#xD;
             HER2 positive patients.&#xD;
&#xD;
          9. Willing to provide clinicopathological information and imaging information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients received systemic treatment before enrolled or finished adjuvant chemotherapy&#xD;
             less than 6 months.&#xD;
&#xD;
          2. With second primary malignant diseases.&#xD;
&#xD;
          3. Other situations assessed by investigator can disturb quality control of the&#xD;
             investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Liu</last_name>
    <phone>+86-18001753364</phone>
    <email>liujing23@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chenfei Zhou</last_name>
    <phone>+86-13761618390</phone>
    <email>raining_grayday@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
      <phone>+86-13818332497</phone>
      <email>junzhang10977@sjtu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Chair of Department of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

